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ABSTRACT 
Evaluating Immunogenicity of African Swine Fever Virus 9GL and CD2v Antigens  
(May 2013) 
 
Kimberley Michelle DeBlois  
Department of Veterinary Pathobiology  
Texas A&M University  
 
Research Advisor: Dr. Waithaka Mwangi 
Department of Veterinary Pathobiology  
 
Swine and wild boars in Africa, and parts of Europe and Russia continue being decimated by a 
severe form of hemorrhagic fever known as African Swine Fever (ASF). This viral disease has 
been responsible for the deaths of millions of swine and poses a significant risk to the United 
States pork industry since it is easily transmitted across continents. However, there is no vaccine 
or treatment available and thus, it is important to develop a vaccine that can prevent future 
infections, and reduce the economic and social impacts resulting from this disease. My research 
will focus on generating recombinant lentivirus expressing 9GL and CD2v ASFV antigens which 
will be used to evaluate antigen-specific cytotoxic T cell responses in pigs immunized with 
recombinant adenoviruses expressing these two antigens. 
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CHAPTER I 
INTRODUCTION 
African Swine Fever Virus (ASFV) is a foreign animal pathogen that produces severe 
hemorrhagic fever and death in affected swine. With a mortality rate of ~100%, this virus has 
had devastating effects on the food security and economy of the nations in which the virus is 
endemic (1). Although first reported in Kenya, ASFV has expanded its range to various countries 
including Europe, Russia, Brazil, Cuba, and parts of the Middle East (2-4). With no vaccine 
available, disease management has been limited to the mass slaughter of affected swine, leading 
to substantial economic losses. Furthermore, with past outbreaks occurring in neighboring 
countries such as Cuba, there is significant concern due to the possibility of ASFV spreading to 
the US mainland (5, 6). As a result, it is imperative that research be dedicated towards the 
development of a safe and effective vaccine in preparation for potential future outbreaks in 
U.S.A.  
Domestic pigs are most commonly infected by ASFV through virus inhalation, or ingestion of 
products or wastes contaminated with the virus (7). Onset of the disease begins with fever 
(>105⁰F) which persists for the first 2-5 days of infection and dips slightly prior to death. In 
addition, infected pigs are anorexic, dull and huddle together, exhibiting arched backs when 
moved. Disease progress is associated with bloody diarrhea, and eventually hemorrhages of the 
skin, snout, abdomen, and legs. The majority of pigs affected die within the first 5 days of 
infection, and necropsies performed show enlarged spleen, hemorrhages in multiple body organs 
including lymph nodes, and button ulcers in the caecum and colon. The few pigs that survive 
infection remain emaciated and are lifelong carriers of the disease. The presence of survivors and 
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the variety of symptoms suggests that disease presentation and severity could be dependent on 
the ASFV isolate contracted (8).  
The overarching goal of this project in Dr. Mwangi’s laboratory is to develop a safe vaccine that 
will provide immunity against ASFV infections in pigs. In order to accomplish this, my research 
will focus on evaluating immunogenicity of two proteins, 9GL and 151R, which are known to 
contribute to ASFV pathogenicity (Figure 1). The first protein of interest, 9GL has been shown 
to target host cell macrophages and induce plaque formation (9). The second protein of interest, 
151R, is a chaperon protein for 9GL and is essential for virus replication. Furthermore it is 
involved in the expression of the capsid protein p72 (10). My project will involve sub-cloning 
the genes encoding these two proteins into a lentivirus vector and thereafter use the DNA 
constructs to generate recombinant lentivirus expressing the respective antigens. The 
recombinant lentiviruses will be used for  in vitro readouts to evaluate antigen-specific T cell 
responses in pigs immunized with recombinant adenoviruses expressing these antigens.  
 
 
Figure 1: Structure of ASFV virus protein including all 
surface and internal proteins. 
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CHAPTER II 
MATERIALS AND METHODS  
Synthetic genes encoding the 9 GL and 151R proteins were available in the puc57 cloning 
vector. These genes were amplified by PCR using primers that introduced EcoR V and  EcoR I 
restriction sites at the the 5’ and 3’ends respectively. These primers also introduced a FLAG and 
HA tag at the 5’ and 3’ ends, respectively, which allowed the proteins to be easily tracked in later 
experiments using tag-specific antibodies. Once the correct PCR products were obtained, they 
were cloned into the PCR-TOPO Blunt vector, transformed into TOP 10 chemically competent 
cells and subsequently plated on LB agar plates containing carbenicillin antibiotic. The bacterial 
colonies produced on these plates were screened by PCR in order to identify recombinant 
plasmid clones which contained the 9GL and 151R genes. The positive clones identified were 
later sequenced for confirmation of the presence of genes encoding the 9GL and 151R proteins. 
Following sequencing the positive clones were subjected to an EcoR V (5’ end) and EcoR I (3’ 
end) restriction digest and gene cleaned, resulting in the production of the purified genes. These 
genes were then subcloned into a lentivirus vector cut with at the 5’ end with EcoR V and at the 
3’ end with EcoR I restriction enzymes and two constructs designated as pLenti-9GL and pLenti-
151R were generated. These constructs were transformed into Stbl3 chemically competent cells 
and plated onto LB agar plates. Positive clones were identified by EcoR V and EcoR I restriction 
digestion of miniprep DNA. Clones expressing the 9GL and 151R proteins were identified by 
immunocytometric analysis of 293A cells transfected with the miniprep DNA and then probed 
with monoclonal antibodies against the FLAG and HA tags. In addition, protein expression was 
validated using ASFV-specific serum. Clones that successfully expressed the 9GL and 151R 
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proteins were retransformed into Stbl3 chemically competent cells and plated on LB Broth 
containing carbenicillin antibiotic. Midiprep DNA was prepared from these cultures and used to 
transfect 293 FT cells. Protein expression was determined once again through immunocytometric 
analysis using monoclonal antibodies against the FLAG and HA tags as above. Based on 
transfection efficiency, one clone per construct was selected and used to generated the 
recombinant lentivirus designated as Lenti-9GL and Lenti-151R, respectively.  
Once the Lenti-9GL and Lenti-151R constructs are produced, they will be amplified, validated 
for protein expression, and virus titers will be determined ready for in vitro evaluation of T cell 
response.  
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CHAPTER III 
RESULTS  
In the course of this experiment we have been successful in isolating the 9GL and 151R inserts 
from the puc57 vector. Insertion into the TOPO-Blunt vector and subsequent transformation into 
TOP 10 cells produced colonies which showed the presence of these inserts when screened by 
PCR. These colonies were then successfully cut by EcoR V and EcoR I restriction sites and 
subcloned into the lentivirus vector. Transformation of the pLenti 9GL and 151R inserts into 
Stbl3 cells produced a moderate number of colonies which showed the presence of these genes 
when screened by PCR and sequenced.  
Upon generating the miniprep DNA of these positive clones, we were able to transfect 293A 
cells with both the pLenti 9GL and 151R constructs. When transfected with 1𝜇g of miniprep 
DNA, the cells demonstrated 9GL and 151R protein expression, however, the transfection 
efficiency was only ~10-20% (Figure 2-4). However, when 293A cells were transfected with 2𝜇g 
of the 9GL and 151R miniprep DNA the transfection efficiency increased to ~50%. This 
suggests that the 293A cells are not suitable candidates for use in determining transfection 
efficiency and protein expression of the pLenti constructs. 
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Figure 2: 293A cells transfected with miniprep DNA showing 9GL 
protein expression  
Figure 3: 293A cells transfected with miniprep DNA showing 9GL 
protein expression  
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Although we have shown through expression staining of 293A cells that we can successfully 
produce the 9GL and 151R proteins, we have been unable to show protein expression of these 
same genes in the 293FT cells. New 293 FT have been ordered:  the previous batch had been 
contaminated with adenovirus based on assays conducted to determine poor performance.  The 
new cells will be used to generate lentivirus.  
 
 
 
 
Figure 4: 293A cells transfected with miniprep DNA showing 151R protein 
expression. 
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CHAPTER IV 
CONCLUSIONS 
African Swine Fever is a devastating disease that has had a tremendous economic and social 
impact on countries in which it is endemic. With a mortality rate of ~100% it has destroyed the 
pork industry in countries in Africa and Europe and has the potential of becoming a threat to the 
U.S. pork industry. With the increase in concern of the impacts this disease can have socially and 
economically, much research has been devoted into developing some method for controlling the 
effects and spread of this disease. It is our hope that with the successful generation of the 
lentivirus for 9GL, 151R and a multitude of other ASF proteins, that we will be able to 
successfully generate a vaccine that can be safely used on swine in these affected areas. 
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